Allied Market Research
Loading...
0
New
New

Prime Editing and CRISPR Market by Service (Cell Line Engineering, Genome Regulation, Gene Editing, and Gene-Modified Cell Therapy), Application (Biomedical Research & Therapy, Agricultural Research, and Others), and End User (Academic Institutes, Biotechnology & Pharma Companies, and Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2021––2030

A11781
Pages: 271
Jun 2021 | 188 Views
   
Author(s) : Linu Dash
Tables: 119
Charts: 31
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Prime Editing And Crispr Market

Request Now !

The global prime editing and CRISPR market was valued at $2,694.2 million in 2020, and is estimated to reach $23,493.0 million by 2030, growing at a CAGR of 24.3% from 2021 to 2030.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global digital health market. The COVID-19 pandemic has stressed health care system in the world and increased the need for development of healthcare information technology, and remote monitoring services.

Prime editing and CRISPR is a genome editing technology in which the genome of living organism is modified by search and replace technique. Prime editing is composed of two components, namely, engineered prime editing guide RNA (pregRNA) and a prime editor (PE). It includes different genetic engineering tools and techniques for alteration of a particular DNA sequence.

Global-Prime-Editing-and-CRISPR-Market

Get more information on this report : Request Sample Pages

Growth of the global prime editing and CRISPR market is majorly driven by increase in demand for targeted gene manipulation technology; rise in funding from private & government organizations for genomic projects; rise in prevalence of genetic-based diseases; and increase in investments in R&D activities by various healthcare companies. According to medical life science, in March 2021, researchers in Medical College of Georgia in U.S. announced that prime editing expand the genetic toolbox to develop disease animal model and correct genetic problems. Moreover, in January 2020, Department of biotechnology, in India, initiated the Genome India Project (GIP) which aims to collect 10,000 genetic samples from citizens and develop a reference genome. Furthermore, according to the CRISPR Medicine, in 2020, it was announced that prime editing also restored function of genetic defect in patient derived organoids. Prime editing and CRISPR emerging technology is also used in cancer biologic study. Surge in demand for genetically modified crops boosts growth of the market. According to the American Association for the Advancement of Science (AAAS), in 2021, it was reported that researchers in the Chinese Academy of Sciences University in China enhance efficiency of plant gene editing with optimized pegRNA designs.

However, side effects associated with prime editing and CRISPR such as legal and ethical issues of and lack of safety in gene editing are expected to restrict the market growth during the forecast period.

Prime Editing And Crispr Market Segmentation

The prime editing and CRISPR market is segmented on the basis of service, application, end user, and region. By services, the market is categorized into cell line engineering, genome regulation, gene editing, and gene-modified cell therapy. By application, it is divided into biomedical research & therapy, agricultural research, and others. By end user, the market is divided into academic institutes, biotechnology & pharma companies, and contract research organizations. 

Prime Editing and CRISPR Market
By Services

Your browser does not support the canvas element.

Gene Editing segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Region wise, the market is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment review

Depending on service, the gene editing segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to increase in demand for gene editing in targeted drug discovery process and advancements in research for genomic-based diseases. However, the gene modified cell therapy segment is expected to witness considerable market growth during the forecast period, owing to increase in prevalence of chronic diseases, surge in demand for stem cell research activities, and increase in demand for genomic models.

Prime Editing and CRISPR Market
By Application

Your browser does not support the canvas element.

Agriculture Research segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

On the basis of application, the agriculture research segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to surge in demand for genetically mutated crops and increase in funding for plant biotechnology by private and government organizations. However, the biomedical research & therapy segment is expected to witness considerable market growth during the forecast period, owing to increase in prevalence of sickle cell anemia, advancements in R&D in the healthcare sector, and surge in adoption of gene editing.

On the basis of end user, the biotechnology & pharma companies segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to increase in prevalence of chronic and genetic diseases, surge in demand for monoclonal antibodies, vaccines, and use of innovative technology in genetic engineering. However, the academic institution segment is expected to witness considerable market growth during the forecast period, owing to development in research in universities and rise in technological advancements in molecular genetics.

Prime Editing and CRISPR Market
By End User

Your browser does not support the canvas element.

Biotechnology & pharma companies segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

North America accounted for a major share in the prime editing and CRISPR market in 2020, and is expected to maintain its dominance during the forecast period, owing to rise in prevalence of genetic diseases, presence of key players, and advancements in R&D in genetic engineering. However, Asia-Pacific is expected to register highest CAGR of 28.1% from 2021 to 2030, owing to increase in prevalence of chronic diseases, rise in geriatric population, increase in demand for novel drugs, and rise in number of laboratories for research.

Key players operating in the global market include Beam Therapeutics, CRISPR Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies (IDT), Intellia Therapeutics Inc., Inscripta, Precision Bioscience, Sangoma Therapeutics, and Synthego Corporation.

Prime Editing and CRISPR Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the prime editing and CRISPR market, and the current trends and future estimations to elucidate imminent investment pockets
  • It presents a quantitative analysis of the prime editing and CRISPR market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities
  • Extensive analysis of the prime editing and CRISPR market based on procedures and services assists to understand the trends in the industry
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the prime editing and CRISPR market

Key Market Segments

By Service

  • Cell Line Engineering
  • Genome Regulation
  • Gene Editing
  • Gene-Modified Cell Therapy

By Application

  • Biomedical Research & Therapy
  • Agricultural Research
  • Others

By End User

  • Academic Institutes
  • Biomedical Research & Therapy
  • Agricultural Research
  • Others
  • Biotechnology & Pharma Companies
  • Biomedical Research & Therapy
  • Agricultural Research
  • Others
  • Contract Research Organizations
  • Biomedical Research & Therapy
  • Agricultural Research
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players 

  • Beam Therapeutics
  • CRISPR Therapeutics
  • GenScript Biotech
  • Horizon Discovery
  • Integrated DNA Technologies (IDT
  • Intellia Therapeutics Inc.,
  • Inscripta
  • Precision Bioscience
  • Sangoma Therapeutics
  • Synthego Corporation
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Advancements in R&D in genetic engineering
3.5.1.2.Increase in demand for genetically modified crops
3.5.1.3.Surge in prevalence of chronic and genetic diseases

3.5.2.Restraints

3.5.2.1.Legal and ethical issues
3.5.2.2.Lack of safety toward gene editing

3.5.3.Opportunity

3.5.3.1.Increase in R&D by major key players and decrease in cost of genomic sequencing

3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on the prime editing and CRISPR market

CHAPTER 4:PRIME EDITING AND CRISPR MARKET, BY SERVICE

4.1.Overview

4.1.1.Market size and forecast

4.2.Cell line engineering

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Genome Regulation

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Gene editing

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Gene-modified cell therapy

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:PRIME EDITING AND CRISPR MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Biomedical research and therapy

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Agricultural Research

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

5.4.Others 

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

CHAPTER 6:PRIME EDITING AND CRISPR MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Academic institutions

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.2.4.Academic institutions, by application

6.3.Biotechnology & pharma companies

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.3.4.Biotechnology & pharma companies, by application

6.4.Contract Research Organizations

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
6.4.4.Contract research organizations, by application

CHAPTER 7:PRIME EDITING AND CRISPR MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America prime editing and CRISPR market, by service
7.2.3.North America  prime editing and CRISPR market, by application
7.2.4.North America  prime editing and CRISPR market, by end user
7.2.5.Market size and forecast, by country

7.2.5.1.U.S.

7.2.5.1.1.U.S. prime editing and CRISPR market, by service
7.2.5.1.2.U.S. prime editing and CRISPR market, by application
7.2.5.1.3.U.S. prime editing and CRISPR market, by end user

7.2.5.2.Canada

7.2.5.2.1.Canada prime editing and CRISPR market, by service
7.2.5.2.2.Canada prime editing and CRISPR market, by application
7.2.5.2.3.Canada prime editing and CRISPR market, by end user

7.2.5.3.Mexico

7.2.5.3.1.Mexico prime editing and CRISPR market, by service
7.2.5.3.2.Mexico prime editing and CRISPR market, by application
7.2.5.3.3.Mexico prime editing and CRISPR market, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe  prime editing and CRISPR market, by service
7.3.3.Europe  prime editing and CRISPR market, by application
7.3.4.Europe  prime editing and CRISPR market, by end user
7.3.5.Market size and forecast, by country

7.3.5.1.Germany

7.3.5.1.1.Germany prime editing and CRISPR market, by service
7.3.5.1.2.Germany prime editing and CRISPR market, by application
7.3.5.1.3.Germany prime editing and CRISPR market, by end user

7.3.5.2.France

7.3.5.2.1.France prime editing and CRISPR market, by service
7.3.5.2.2.France prime editing and CRISPR market, by application
7.3.5.2.3.France prime editing and CRISPR market, by end user

7.3.5.3.UK

7.3.5.3.1.UK prime editing and CRISPR market, by service
7.3.5.3.2.UK prime editing and CRISPR market, by application
7.3.5.3.3.UK prime editing and CRISPR market, by end user

7.3.5.4.Italy

7.3.5.4.1.Italy prime editing and CRISPR market, by service
7.3.5.4.2.Italy prime editing and CRISPR market, by application
7.3.5.4.3.Italy prime editing and CRISPR market, by end user

7.3.5.5.Spain

7.3.5.5.1.Spain prime editing and CRISPR market, by service
7.3.5.5.2.Spain prime editing and CRISPR market, by application
7.3.5.5.3.Spain prime editing and CRISPR market, by end user

7.3.5.6.Rest of Europe

7.3.5.6.1.Rest of Europe prime editing and CRISPR market, by service
7.3.5.6.2.Rest of Europe prime editing and CRISPR market, by application
7.3.5.6.3.Rest of Europe prime editing and CRISPR market, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific prime editing and CRISPR market, by service
7.4.3.Asia-Pacific  prime editing and CRISPR market, by application
7.4.4.Asia-Pacific  prime editing and CRISPR market, by end user
7.4.5.Market size and forecast, by country

7.4.5.1.Japan

7.4.5.1.1.Japan prime editing and CRISPR market, by service
7.4.5.1.2.Japan prime editing and CRISPR market, by application
7.4.5.1.3.Japan prime editing and CRISPR market, by end user

7.4.5.2.China

7.4.5.2.1.China prime editing and CRISPR market, by service
7.4.5.2.2.China prime editing and CRISPR market, by application
7.4.5.2.3.China prime editing and CRISPR market, by end user

7.4.5.3.Australia

7.4.5.3.1.Australia prime editing and CRISPR market, by service
7.4.5.3.2.Australia prime editing and CRISPR market, by application
7.4.5.3.3.Australia prime editing and CRISPR market, by end user

7.4.5.4.India

7.4.5.4.1.India prime editing and CRISPR market, by service
7.4.5.4.2.India prime editing and CRISPR market, by application
7.4.5.4.3.India prime editing and CRISPR market, by end user

7.4.5.5.South Korea

7.4.5.5.1.South Korea prime editing and CRISPR market, by service
7.4.5.5.2.South Korea prime editing and CRISPR market, by application
7.4.5.5.3.South Korea prime editing and CRISPR market, by end user

7.4.5.6.Rest of Asia-Pacific

7.4.5.6.1.Rest of Asia-Pacific prime editing and CRISPR market, by service
7.4.5.6.2.Rest of Asia-Pacific prime editing and CRISPR market, by application
7.4.5.6.3.Rest of Asia-Pacific prime editing and CRISPR market, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA prime editing and CRISPR market, by service
7.5.3.LAMEA prime editing and CRISPR market, by application
7.5.4.LAMEA prime editing and CRISPR market, by end user
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil

7.5.5.1.1.Brazil prime editing and CRISPR market, by service
7.5.5.1.2.Brazil prime editing and CRISPR market, by application
7.5.5.1.3.Brazil prime editing and CRISPR market, by end user

7.5.5.2.Saudi Arabia

7.5.5.2.1.Saudi Arabia prime editing and CRISPR market, by service
7.5.5.2.2.Saudi Arabia prime editing and CRISPR market, by application
7.5.5.2.3.Saudi Arabia prime editing and CRISPR market, by end user

7.5.5.3.South Africa

7.5.5.3.1.South Africa prime editing and CRISPR market, by service
7.5.5.3.2.South Africa prime editing and CRISPR market, by application
7.5.5.3.3.South Africa prime editing and CRISPR market, by end user

7.5.5.4.Rest of LAMEA

7.5.5.4.1.Rest of LAMEA prime editing and CRISPR market, by service
7.5.5.4.2.Rest of LAMEA prime editing and CRISPR market, by application
7.5.5.4.3.Rest of LAMEA prime editing and CRISPR market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.Beam Therapeutics Inc

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments

8.2.CRISPR Therapeutics AG.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments

8.3.Genscript Biotech Corporation.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.Horizon Discovery, Ltd.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Integrated DNA Technologies (IDT).

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments

8.6.Intellia Therapeutics, Inc.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Key strategic moves and developments

8.7.Inscripta, Inc

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments

8.8.Precision Biosciences

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.Sangamo Therapeutics.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.Synthego Corporation.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments

LIST OF TABLES

TABLE 01.PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 02.PRIME EDITING AND CRISPR MARKET FOR CELL LINE ENGINNERING, BY REGION, 2020–2030 ($MILLION)
TABLE 03.PRIME EDITING AND CRISPR MARKET FOR REGULATION OF GENE, BY REGION, 2020–2030 ($MILLION)
TABLE 04.PRIME EDITING AND CRISPR MARKET FOR GENE EDITING, BY REGION, 2020–2030 ($MILLION)
TABLE 05.PRIME EDITING AND CRISPR MARKET FOR GENE MODIFIED CELL THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 07.PRIME EDITING AND CRISPR MARKET FOR BIOMEDICAL RESEARCH AND THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 08.PRIME EDITING AND CRISPR MARKET FOR AGRICULTURAL RESEARCH, BY REGION, 2020–2030 ($MILLION)
TABLE 09.PRIME EDITING AND CRISPR MARKET FOR OTHER RESEARCH, BY REGION, 2020–2030 ($MILLION)
TABLE 10.GLOBAL PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 11.PRIME EDITING AND CRISPR MARKET FOR ACADEMIC INSTITUTIONS, BY REGION, 2020–2030 ($MILLION)
TABLE 12.ACADEMIC INSTITUTIONS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 13.PRIME EDITING AND CRISPR MARKET FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY REGION, 2020–2030 ($MILLION)
TABLE 14.BIOTECHNOLOGY & PHARMA COMPANIES, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 15.PRIME EDITING AND CRISPR MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY REGION, 2020–2030 ($MILLION)
TABLE 16.CONTRACT RESEARCH ORGANIZATIONS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 17.PRIME EDITING AND CRISPR MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA  PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 19.NORTH AMERICA  PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 20.NORTH AMERICA  PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 21.NORTH AMERICA  PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 22.U.S. PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 23.U.S. PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.U.S. PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.CANADA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 26.CANADA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.CANADA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.MEXICO PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 29.MEXICO PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 30.MEXICO PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 31.EUROPE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 32.EUROPE  PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 33.EUROPE  PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 34.EUROPE  PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 35.GERMANY PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 36.GERMANY PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.GERMANY PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.FRANCE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 39.FRANCE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 40.FRANCE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.UK PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 42.UK PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43.UK PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.ITALY PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 45.ITALY PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.ITALY PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.SPAIN PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 48.SPAIN PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 50.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 51.REST OF EUROPE PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 52.ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC  PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 54.ASIA-PACIFIC  PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 55.ASIA-PACIFIC  PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 56.JAPAN PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 57.JAPAN PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 58.JAPAN PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 59.CHINA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 60.CHINA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 61.CHINA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 63.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 64.AUSTRALIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 65.INDIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 66.INDIA  PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 67.INDIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 69.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 70.SOUTH KOREA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 74.LAMEA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 75.LAMEA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 76.LAMEA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 77.LAMEA  PRIME EDITING AND CRISPR MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 78.BRAZIL PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 79.BRAZIL PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 80.BRAZIL PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 82.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 83.SAUDI ARABIA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 85.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 86.SOUTH AFRICA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY SERVICE, 2020–2030 ($MILLION)
TABLE 88.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 89.REST OF LAMEA PRIME EDITING AND CRISPR MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 90.BEAM: COMPANY SNAPSHOT
TABLE 91.BEAM: OPERATING SEGMENTS
TABLE 92.BEAM: PRODUCT PORTFOLIO
TABLE 93.CPISPR: COMPANY SNAPSHOT
TABLE 94.CRISPR: OPERATING SEGMENTS
TABLE 95.CRISPR: PRODUCT PORTFOLIO
TABLE 96.GENSCRIPT: COMPANY SNAPSHOT
TABLE 97.GENSCRIPT: OPERATING SEGMENTS
TABLE 98.GENSCRIPT: PRODUCT PORTFOLIO
TABLE 99.HORIZON: COMPANY SNAPSHOT
TABLE 100.HORIZON: OPERATING SEGMENTS
TABLE 101.HORIZON: PRODUCT PORTFOLIO
TABLE 102.IDT: COMPANY SNAPSHOT
TABLE 103.IDT: OPERATING SEGMENTS
TABLE 104.IDT: PRODUCT PORTFOLIO
TABLE 105.INTELLIA: COMPANY SNAPSHOT
TABLE 106.INTELLIA: OPERATING SEGMENTS
TABLE 107.INTELLIA: PRODUCT PORTFOLIO
TABLE 108.INSCRIPTA: COMPANY SNAPSHOT
TABLE 109.INSCRIPTA: OPERATING SEGMENTS
TABLE 110.INSCRIPTA: PRODUCT PORTFOLIO
TABLE 111.PRECISION COMPANY SNAPSHOT
TABLE 112.PRECISION: OPERATING SEGMENTS
TABLE 113.PRECISION: PRODUCT PORTFOLIO
TABLE 114.SANGAMO: COMPANY SNAPSHOT
TABLE 115.SANGAMO: OPERATING SEGMENTS
TABLE 116.SANGAMO: PRODUCT PORTFOLIO
TABLE 117.SYNTHEGO: COMPANY SNAPSHOT
TABLE 118.SYNTHEGO: OPERATING SEGMENTS
TABLE 119.SYNTHEGO: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.PRIME EDITING AND CRISPR MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR REGULATION OF GENOME, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR GENE EDITING, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR GENE MODIFIED CELL THERAPY, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR BIOMEDICAL RESEARCH AND THERAPY, BY COUNTRY,  2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR AGRICULTURAL RESEARCH, BY COUNTRY,  2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR OTHER RESEARCH, BY COUNTRY,  2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR BIOTECHNOLOGY & PHARMA COMPANIES, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PRIME EDITING AND CRISPR MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2020–2030 (%)
FIGURE 23.GENSCRIPT: NET SALES, 2018-2020 ($MILLION)
FIGURE 24.GENSCRIPT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 25.GENSCRIPT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26.HORIZON: NET SALES, 2017-2019 ($MILLION)
FIGURE 27.HORIZON: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.HORIZON: REVENUE SHARE BY REGION 2019 (%)
FIGURE 29.PRECISION: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.PRECISION: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.SANGAMO: NET SALES, 2018–2020 ($MILLION)

 
 

According to analyst perspective, growth of the prime editing and CRISPR market is attributed to factors such as technological advancements in R&D for genetics; rise in prevalence of chronic and genetic diseases such as sickle cell anemia, cystic fibrosis, disease due to point mutation, and lung cancer; increase in funds from private and government organizations for genetic research, and surge in demand for monoclonal antibodies and vaccines. The prime editing and CRISPR market gains interest of biotechnology & pharma companies, owing to surge in demand for vaccine and regenerative medicine. This leads to increase in adoption of genetic engineering. Moreover, the market has gained high traction in laboratories and universities in recent years as these tools are used in gene editing.

Further, North America is expected to witness highest growth, in terms of revenue, owing to rise in prevalence of genetic diseases, presence of key players, and advancements in R&D in genetic engineering.

Asia-Pacific was the second-largest contributor to the market in 2020, and is expected to register fastest CAGR during the forecast period, owing to increase in prevalence of chronic diseases, rise in geriatric population, increase in demand for novel drugs, and rise in number of laboratories for research.

In addition, lack of safety and legal ethical issues related to gene editing in human germ line is anticipated to restrain the market growth during the forecast period.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of prime editing and CRISPR Market is $2,694.2 million in 2020.

A. The forecast period in the report is from 2021 to 2030

A. The market value of prime editing and CRISPR Market in 2021 was $3,327.3 Million

A. The base year for the report is 2020.

A. Yes, prime editing and CRISPR companies are profiled in the report

A. The top companies that hold the market share in prime editing and CRISPR Market are Beam Therapeutics, CRISPR Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies (IDT), Intellia Therapeutics Inc., Inscripta, Precision Bioscience, Sangoma Therapeutics, Synthego Corporation.

A. No, there is no value chain analysis provided in the prime editing and CRISPR Market report

A. The key trends in the prime editing and CRISPR Market are rise in R&D in genetic engineering, increase in prevalence of genetic based disease, and surge in demand for genetically modified crops

Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Prime Editing and CRISPR Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers